You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Midtreatment Evaluation of Lymphoma Response to Chemotherapy by Volume Perfusion Computed Tomography

Spira, Daniel MD*; Grünwald, Leonard*; Vogel, Wichard MD; Sauter, Alexander MD*; Spira, Sven Michael MSc; Claussen, Claus Detlef MD*; Horger, Marius MD*

Journal of Computer Assisted Tomography:
doi: 10.1097/RCT.0b013e3182a90ee7
Abdominal Imaging

Objective: The aim of this study was to search for chemotherapy-induced perfusion changes of diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma at midtreatment versus baseline volume perfusion computed tomography (VPCT).

Methods: Forty-five consecutive patients with untreated diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma received VPCT examinations of the tumor bulk at baseline and during chemotherapy (midtreatment). Blood flow (BF), blood volume (BV), and transit constant (K-trans) were determined. Treatment response was categorized according to the Cheson criteria into complete or partial remission and stable or relapsed/progressive disease.

Results: Midtreatment follow-up showed a reduction in BF, BV, and K-trans in all lymphoma subtypes compared with baseline. The reduction in BV was less pronounced in larger tumors. Notably, BF, BV, and K-trans decreased in the responders (complete remission/partial remission) when compared with the nonresponders (stable or relapsed/progressive disease). Less than 10% reduction in BF was shown to be the best VPCT criterion for the identification of nonresponse.

Conclusions: Chemotherapy-induced perfusion changes in responders are recognizable at midtreatment VPCT.

Author Information

From the *Department of Diagnostic and Interventional Radiology, and †Department of Oncology and Hematology, Eberhard-Karls-University, Tübingen, Germany; and ‡Finance Department, HEC Paris, Jouy en Josas, France.

Received for publication April 9, 2013; accepted August 12, 2013.

Reprints: Daniel Spira, MD, Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany (e-mail:

Claus Detlef Claussen received technical support supplied by Siemens Healthcare (Forchheim, Germany). Daniel Spira was supported by an intramural grant of the Eberhard-Karls-University Tuebingen (project number 263-0-0). The other authors declare no conflict of interest.

© 2014 by Lippincott Williams & Wilkins